TOKYO (Reuters) – Japan’s Chugai Pharmaceutical Co said on Monday it has applied to regulators to expand the use of an antibody treatment for COVID-19 to also allow for preventative care.
Japanese regulators approved an antibody cocktail known as Ronapreve as a treatment for COVID-19 in July. The latest filing seeks to use the drug as both a prophylaxis for COVID-19 and as treatment of asymptomatic cases, Chugai said in a release.
(Reporting by Rocky Swift, Editing by Timothy Heritage)
